Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Continuing Education

CONTINUING EDUCATION AGENDA

MONDAY, AUGUST 27

5:00 p.m. – 6:20 p.m.

Opening Plenary (Continuing Education: CE – PL1)

PL1.  Building a Status Neutral World: Harmonizing the Missions of HIV and STD Control

Demetre Daskalakis, MD, MPH, Deputy Commissioner, Department of Health and Mental Hygiene, Long Island City, New York

TUESDAY, AUGUST 28

8:00 a.m. – 9:00 a.m.

Plenary Session 1 (Continuing Education: CE – PL2)

PL2.  Opioids and STDs

Opioids, Pregnancy, and STIs: Intersection Of Reproductive and Behavioral Health

Mishka Terplan, MD, MPH, FACOG, DFASAM, Professor Obstetrics & Gynecology and Psychiatry, Associate Director Addiction Medicine, Virginia Commonwealth University, Richmond, VA

Opioids and Infectious Disease: Leveraging Data From A Syndemic To Address Public Health

Gregorio Millett, MPH, Vice President and Director, Public Policy, amfAR, The Foundation for AIDS Research, Washington, DC

9:30 a.m. – 10:30 a.m.

Mini-Plenary Session 1  and 2:

Mini-Plenary 1  (Continuing Education: CE – A1)

A1. Networks Analysis: Characterizing Epidemics; Assessing Interventions and Building Transmission Models

Network Characterization and Intervention in Dual Syphilis HIV Epidemics

John Schneider, MD, MPH, Associate Professor of Medicine and Epidemiology, University of Chicago, Chicago, IL

 Contrasting Disease Contagion with Behavioral Diffusion: Network Factors that Accelerate or Inhibit Prevalence   

Thomas Valente, PhD, Professor and Interim Chair, Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA

Insights Into Transmission Networks Provided by Analysis of HIV Sequence Data and Population Genetic Modeling

Erik Volz, PhD, Senior Lecturer, Department of Infectious Disease Epidemiology, Imperial College London, United Kingdom, London

Mini-Plenary 2  (Continuing Education: CE – A2)

A2. Innovations in the Pipeline: STD Vaccines and Novel Antibiotics

Recent Advances in Animal Modeling for Gonorrhea Vaccine Research

Ann Jerse, PhD, Full Professor,  Department of Primary Appointment: Microbiology & Immunology, Uniformed Services University, Bethesda, MD

Old Drugs, New Drugs and New Approaches to an Emerging Global Public Health Threat

Edward Hook, III, MD, Professor, University of Alabama School of Medicine, Birmingham, AL

Topical Prevention of STI & HIV: Advances & Controversies

Jeanne Marrazzo, MD, MPH, Professor & Director, Division of Infectious Diseases, University of Alabama at Birmingham School of Medicine, Birmingham, AL

10:45am-12:00pm

Concurrent Sessions 1A – E

B1. 1D – Symposium: Women’s Health  (Continuing Education: CE – B1)

The Impact of Medicaid Expansion on Prenatal Care Access

Aaron Lopata, MD, MPP, Chief Medical Officer, Maternal and Child Health Bureau, Health Resources and Services Administration (HRSA), Rockville, MD

Programmatic Responses to CS and the Critical Role of Prenatal Care

Chaquetta Johnson, DNP, MPH, APRN, WHNP-BC, Deputy Director – Operations, Louisiana STD/HIV Program, New Orleans, LA

Working With Family Planning To Reach Women At Increased Risk

George Walton, MPH, MLS(ASCP)CM,  STD Program Manager, Bureau of HIV, STD, and Hepatitis, Des Moines, IA

The Population-Level Impact of Screening Women for Chlamydia

Minttu Rönn, PhD, Research Associate, Department of Global Health and Population, Harvard T. H. Chan School of Public Health, Boston, MA

B2. 1E – Symposium: Changing Paradigms for STI Diagnostics (Continuing Education: CE – B2)

The Customer is Often Right: Innovative Solutions in the Local Public Health Laboratory

Godfred Masinde, DPH, PhD, MBA, HCLD(ABB), DRI (CA), Laboratory Director, San Francisco Public Health Laboratory, San Francisco, CA

Point of Care Diagnosis of Chlamydia and Gonorrhea in Nontraditional Health Care Settings

Lea, MD  Assistant Professor, Division of Adolescent and Transition Medicine, Cincinnati Children’s Hospital Medical Center

University of Cincinnati School of Medicine, Cincinnati, Ohio

What’s on the Way and Where Will It Take Us?

Barbara Van Der Pol, PhD, MPH, Associate Professor of Medicine / STD Diagnostics Lab Director, University of Alabama at Birmingham School of Medicine, Birmingham, AL

1:30 p.m. – 2:30 p.m.

Plenary 2 (Continuing Education: CE – PL3)

PL3.  Defining STD Program Success in 2018

Defining STD Program Success: The Local Public Health Perspective

Matthew Golden, MD, MPH, Director and Professor, Public Health Seattle-King County HIV/STD Program, University of Washington Harborview Medical, Center, Seattle, WA

STI Control in the 21st Century: Can the past inform the future?

Laura Bachmann, MD, MPH, Chief Medical Officer, Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, GA

3:00 p.m. – 4:15 p.m.

Concurrent Sessions 2A – F

C1. 2D – Symposium: The Future of Partner Management and Treatment  (Continuing Education: CE – C1)

PN, PN!  Wherefore art thou, PN?

Thomas Peterman, MD, MSc, Team Lead, Field Epidemiology Unite, Epidemiology and Statistics Branch,  Centers for Disease Control and Prevention, Atlanta, GA

Prioritization and Resource Management at the State Level

Sydney Minnerly, MA, Partner Services Coordinator, Texas Department of State Health Services, Austin, TX

Optimizing the Impact of Expedited Partner Therapy

Julie Schillinger, MD, MSc, CDC Assignee, Director of Surveillance, Epidemiology and Special Projects, Bureau of STD Control, New York City Department of Health and Mental Hygiene, New York, NY

The Role of Disease Intervention for Infectious Syphilis: Challenges and Opportunities

Heidi Bauer, MD, MS, MPH, Chief, Sexually Transmitted Diseases Control Branch,  Division of Communicable Disease Control, Center for Infectious Diseases, California Department of Public Health, Richmond, CA

C2. 2E – Symposium:  STD Program Partnerships for Better STD Prevention and Control; Integrating Family Planning, HIV Prevention and STD Prevention (Continuing Education: CE – C2)

Family Planning Integration

Clare Coleman, BA, President & CEO, National Family Planning & Reproductive Health Association (NFPRHA), Washington, DC

STeP Up the Fight Against STDs:  Screening, Treatment, Prevention:  How Community Health Centers Can Help Stem the Tide

Marwan Haddad, MD, MPH, AAHIVS, Medical Director, Center for Key Populations, Community Health Center, Inc., Meriden, CT

Transitioning from Family Planning and STD Services to a Comprehensive Reproductive Health Model:  The Louisiana Experience

DeAnn Gruber, PhD, LCSW, Director, Bureau of Infectious Diseases, Louisiana Department of Health, New Orleans, LA

Promoting Sexual Health by Integrating STD,HIV, and Contraception Services

Susan Blank, MD, MPH, Assistant Commissioner, Bureau of STD and Prevention at the New York City Department of Health & Mental Hygiene, Long Island City, NY

4:35 p.m. – 5:05 p.m.

D1. Debate 1 – It is time to Implement Doxycycline Prophylaxis for Syphilis (Continuing Education: CE – D1)

Stephanie Cohen, MD, MPH, Medical Director, City Clinic, Section Director, HIV and STD, San Francisco Department of Public Health, San Francisco, CA

Myron Cohen, MD, Director, Institute for Global Health and Infectious Diseases, Chief, Division of Infectious Diseases, University Of North Carolina At Chapel Hill, NC

WEDNESDAY, AUGUST 29

8:00 a.m. – 9:00 a.m.

Plenary 3

PL4.   The Role of Technology and Health (Continuing Education: CE – PL4)

eHealth Interventions To Increase STI And HIV Testing For Men Who Have Sex With Men 

Patrick Sullivan, PhD, Professor, Rollins School of Public Health, Atlanta, GA

Utilizing Digital Health to Improve Adolescent Sexual Health: Opportunities and Challenges

Laura Widman, PhD, Assistant Professor, Department of Psychology

North Carolina State University, Chapel Hill, NC

9:30 a.m. – 10:30 a.m.

Mini-Plenary Session 3  and 4:

Mini-Plenary 3

E1. Drivers of Antimicrobial Resistance: The Community, the Individual and the Pathogen  (Continuing Education: CE – E1)

Antimicrobial Resistant Gonorrhea in the United States

Sancta St. Cyr, MD, Medical Officer, Gonococcal Isolate Surveillance Project (GISP), Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, GA

Molecular Tools to Examine Antibiotic Resistant N. gonorrhoeae 

David Whiley, PhD, Faculty of Medicine, The University of Queensland, Royal Brisbane Hospital, Brisbane, Queensland, Australia

Gonorrhea Treatment and Antimicrobial Resistance: Is There a Connection?

Lindley Barbee, MD MPH, Assistant Professor, Infectious Diseases, University of Washington, Medical Director, Public Health, Seattle & King County STD Program, Seattle, WA

Mini-Plenary 4

E2. Sex, Money and Power: Sex Trafficking; Sexual Harassment; Sexual Discrimination (Continuing Education: CE – E2)

Human Trafficking-Hiding in Plain Sight

Hanni Stoklosa, MD, MPH, Emergency Physician, Brigham and Women’s Hospital, Boston, MA

Pornography: The Industry that Hijacks the Healthy Sexual Development of Youth

Gail Dines, PhD,  Professor, Emerita of Wheelock College and CEO of Culture Reframed, Chestnut Hill, MA

Bullying and Discrimination Toward Sexual Minorities

Stephen Russell, PhD, MA, Professor of Human Development and Family Sciences, University of Texas, Austin, TX

10:45 a.m. – 12:00 p.m.

Concurrent Sessions 3A – E

F1. 3D – Symposium: Improving Provider Practice; Overcoming Barriers (Continuing Education: CE – F1)

I CaRe: A Virtual Learning Collaborative to Improve Adolescent Sexual Health in Pediatric Primary Care 

Gale Burstein, MD, MPH, Commissioner, Erie County Department of Health; Clinical Professor of Pediatrics, Jacobs School of Medicine, Buffalo, NY

Transforming Primary Care for LGBT People 

Bruce Furness, MD, MPH, FACPM USPHS, CDC Medical Epidemiologist, Division of STD/TB Control, Washington, DC

Socio-ecological influences of young men’s use of sexual & reproductive healthcare: Implications for the practitioner

Arik Marcell, MD, MPH, Associate Professor, Division of General Pediatrics and Adolescent Medicine, Departments of Pediatrics and Population, Family & Reproductive Health, The Johns Hopkins University, Baltimore, MD

A Practical Roadmap for the Public: Five Action Steps to Good Sexual Health

Susan Gilbert, MPA, Co-Director, National Coalition for Sexual Health (NCSH), Altarum, Arlington, VA

F2. 3E – Symposium: Increasing STD Screening Across Populations and Contexts (Continuing Education: CE – F2)

Sexual & Reproductive walk-in clinic redesign-creating comprehensive, low barrier, low cost, patient centered access

Chad Hendry, Director of Sexual and Reproductive Health, Howard  Brown  Health, Chicago, IL

eHealth and At Home Approaches to Extragenital STD and HIV Screening among Young MSM

Brian Mustanski, PhD, Director, Institute for Sexual and Gender Minority Health and Wellbeing, Northwestern University, Feinberg School of Medicine, Chicago, IL

Participatory Approach to Increasing Chlamydia Screening Rates in Title X Family Planning Clinics:  A Double Digit improvement

Amy Peterson, MPH, STD Program Specialist, Michigan Department of Health and Human Services, Division of HIV and STD Programs, STD Section, Detroit, MI

Riding the Quality Improvement Wave: Building Public Health-Primary Care Partnerships to Improve Chlamydia Screening in a High Morbidity County

Laura Kovaleski, MPH, Women’s, Adolescent and Correctional Health Unit Chief, STD Control Branch, California Department of Public Health, California

1:30 p.m. – 2:30 p.m.

Plenary Session 4 (Continuing Education: CE – PL5)

PL5.  Our Changing Environment and Implications for STD Prevention Science and Policy

The Changing Healthcare Landscape

Naomi Seiler, JD, Associate Professor, Department of Health Policy and Management, George Washington University School of Public Health, Washington, DC

Prioritizing STD Prevention Going Forward

John Auerbach, MBA, President and Chief Executive Officer, Trust for America’s Health, Washington, DC

3:00 p.m. – 4:15 p.m.

Concurrent Sessions 4A – F

G1. 4D – Symposium: Programmatic Approaches to Stemming the Tide of Resistant STI (Continuing Education: CE – G1)

Using Real-time Molecular Neisseria gonorrhoeae Susceptibility Data in a Large Health System to Modify Antibiotic Use and Reduce the Emergence of Resistance

Jeffrey Klausner, MD, MPH, Professor of Medicine and Public Health, University of California, Los Angeles, CA

Strengthening the U.S. response to resistant gonorrhea (SURRG): Building local rapid detection and response capacity

Karen Schlanger, PhD, MPH, Project Lead, Strengthening U.S. Response to Resistant Gonorrhea (SURRG), Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, GA

SURRGing forward in Denver, Colorado

Karen Wendel, MD, Director HIV/ STD Prevention and Control, Denver Public Health, Denver, CO

Modeling Diagnosis and Treatment Policies to Slow and Control Resistance  

Yonatan Grad, MD, PhD, Assistant Professor of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, MA

G2. 4E – Symposium:  Emerging/Re-emerging and Neglected STI (Continuing Education: CE – G2)

Update On Neisseria meningitidis Urethritis in the U.S.: What Have We Learned So Far?

Jose Bazan, DO, Medical Director, Sexual Health Clinic Columbus Public Health, The Ohio State University College of Medicine, Division of Infectious Diseases, Columbus, OH

Shigellosis As A Sexually Transmitted Infection Among Men Who Have Sex With Men In Massachusetts: A Spatial Epidemiological Approach  

Thomas Stopka, PhD, MHS, Assistant Professor, Department of Public Health and Community Medicine, Clinical and Translational Science Institute, Tufts University School of Medicine, Boston, MA

Sexual Transmission of Zika Virus Infection: What We’ve Learned and What We Still Don’t Know

John Brooks, MD, Senior Medical Advisor, Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, GA

Are We Ready To Take Mycoplasma genitalium Seriously?

Lisa Manhart, PhD, Professor, Epidemiology & Global Health (adjunct), Center for AIDS and STD, University of Washington, Seattle, WA

4:35 p.m. – 5:05 p.m.

H. Debate 2 Should Health Departments Stop Active Surveillance and Partner Services for Chlamydia? (Continuing Education: CE – H)

Joan Chow, DrPH, MPH, Chief, Surveillance, Epidemiology, Assessment, and Evaluation Section,  Sexually Transmitted Disease Control Branch, California Department of Public Health, Richmond, CA

William (Bill) Miller, MD, PhD, MPH, Professor and Chair, Division of Epidemiology, The Ohio State University, Columbus, OH

5:10 p.m. – 6:00 p.m.

I. Panel Discussion

Improving Partner Services for Syphilis among Gay and Bisexual Men (Continuing Education: CE – I)

Thomas Bertrand, MPH, MA, Chief, Office of HIV, STDs, Viral Hepatitis and TB, Rhode Island Department of Health, Providence, Rhode Island

Kenneth Mayer, MD, Infectious Disease Attending and Director of HIV Prevention Research, Harvard Medical School, Medical Research Director, The Fenway Institute, Boston, MA

Susan Philip, MD, MPH, Deputy Health Officer, Director, Disease Prevention and Control Branch, Population Health Division, San Francisco Department of Public Health, San Francisco, CA

THURSDAY, AUGUST 30

8:00 a.m. – 9:15 a.m.

Concurrent Sessions 5A – F

J1. 5D – Symposium: Transgender Care: Update and Progress (Continuing Education: CE – J1)

An Overview of The Lives of Transgender People in The United States: Results From the 2015 U.S. Transgender Survey

Sandy James, JD PhD, Researcher, Former Research Director, National Center for Transgender Equality, Washington, DC

What do we know about PrEP for transgender people?

Kevin Ard, MD, MPH, Director, Massachusetts General Hospital Sexually Transmitted Disease Clinic, Massachusetts General Hospital, Boston, MA

Language Matters: Creating The Environment to Provide Care for Transgender Patients

Paula Neira, JD, MSN, RN, CEN, Clinical Program Director, Johns Hopkins Center for Transgender Health, Baltimore, MD

J2. 5E – Symposium:  Innovations in STD Prevention: Informatics; Clinic Operations and Surveillance (Continuing Education: CE – J2)

Converting Guidelines Into Clinical Decision Support In The EMR At The Point Of Care

Blackford Middleton, MD, MPH, MSc, FACP, FACMI, FHIMSS, Chief Informatics and Innovation Officer, Apervita, Inc., Chicago, IL

National Efforts To Pilot Electronic Case Reporting For Chlamydia And Gonorrhea

Ninad Mishra, MD, MS, Informatics Team Lead, Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, GA

Rethinking STD Surveillance: What are we measuring and why?

Elizabeth Torrone, PhD, MSPH, Team Lead, Surveillance and Special Studies Team, Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, GA

Exploring the Role of Express STD Visits Using A Community of Practice Model

Hilary Reno, MD, PhD, Medical Consultant, CDC Assignee, Division of STD Prevention, University in St. Louis, St. Louis, MO

9:30 a.m. – 10:45 a.m.

Concurrent Sessions 6A – E

K1. 6D – Symposium:  Measuring New Interventions and Their Impact on STD Morbidity (Continuing Education: CE – K1)

Considerations for PrEP Cost-effectiveness in STD Clinics

Thomas Gift, PhD, Branch Chief, Health Service Research & Evaluation Branch, Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, GA

Measuring the Impact of Screening Guidelines on STDs in MSM

Kevin Weiss, MPH, Data Analyst, Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA

Smartphone APP to Reduce Time to Notification of STIs

Adam Cohen, PhD, MPH, Director of Advocacy and Policy Research, Public Health Division, AIDS Healthcare Foundation, Los Angeles, CA

THRIVE: Expanding STD Screening to Reverse the HIV Epidemic

Ashley Carter, MPH, Manger, STD & Viral Hepatitis Policy, Planning & Communications, STD Surveillance, Operations & Data Administration, Division of Disease Prevention, Virginia Department of Health, Richmond, VA

K2. 6E – Symposium:  Innovations in STD Prevention Programs (Continuing Education: CE – K2)

Identifying and Locating STI Clients with a Smartphone

Steve Beagle, BS, Field Coordinator, University of North Carolina/NC DHHS, Raleigh, NC

STI/HIV Public Health Detailing: Expanding our Reach and Engaging  Together with Community Providers 

Jacky Jennings, PhD, MPH, Director, Center for Child & Community Health Research (CCHR) & BEAD Core Johns Hopkins University School of Medicine, Baltimore, MD

Love in the Time of Gonorrhea: Revamping STI Programs in a Modern Era

Travis Gayles, MD, PhD, Chief of Public Health Services, Montgomery County Department of Health and Human Services, Washington DC

Incorporating Negative STD Test Results into an Electronic Lab Reporting System: How  Case Management and Surveillance Benefits 

Scott White, MS, MPH, Epidemiology Manager, Utah Department of Public Health, Salt Lake City, UT

OBJECTIVES

At the conclusion of the session, the participant will be able to:

  1. Discuss at least two examples of clinical management or biomedical intervention that can enhance STD prevention and control efforts.
  2. Explain at least two ways STD diagnostic strategies can enhance STD prevention and control efforts.
  3. Discuss at least two examples of domestic or global STD-related epidemiological or behavioral trends.
  4. Explain at least two methods that can be used to develop, enhance, and evaluate STD surveillance systems.
  5. Summarize how at least two factors within the health services system can affect STD prevention and treatment services.
  6. Describe at least two social and behavioral aspects of STD prevention.
  7. Describe at least two examples of bridging scientific research and public health program management to enhance STD prevention and control efforts.

ACCREDITATION STATEMENTS

CME activities with Joint Providers:  This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the join providership of the Centers for Disease Control and Prevention and the American Sexually Transmitted Diseases Association, the American Sexual Health Association, the National Coalition of STD Directors, the Public Health Agency of Canada, and the Pan American Health Organization.  The Centers for Disease Control and Prevention is accredited by the (ACCME®) to provide medical education for physicians.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The Centers for Disease Control and Prevention designates this live activity for a maximum of 17 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE: The Centers for Disease Control and Prevention is accredited as a provider of Continuing Nursing Education by the American Nurses Credentialing Center’s Commission on Accreditation. This activity provides 16.3 contact hours.

CEU:  The Centers for Disease Control and Prevention is authorized by IACET to offer 1.6 CEU’s for this program.

CECH: Sponsored by the Centers for Disease Control and Prevention, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc.  This program is designated for Certified Health Education Specialists (CHES®) and/or Master Certified Health Education Specialists (MCHES®) to receive up to 18.5 total Category I continuing education contact hours.  Maximum advanced level continuing education contact hours available are 0.  CDC provider number 98614.

For Certified Public Health Professionals (CPH)

The Centers for Disease Control and Prevention is a pre-approved provider of Certified in Public Health (CPH) recertification credits and is authorized to offer 20 CPH recertification credits for this program.

DISCLOSURE:  In compliance with continuing education requirements, all presenters must disclose any financial or other associations with the manufacturers of commercial products, suppliers or commercial services, or commercial supporters as well as any use of unlabeled product(s) or products(s) under investigational use.

CDC, our planners, presenters, and their spouses/partners wish to disclose they have no Financial Interest(s) or other Relationship(s) with the manufacturers of commercial products, suppliers or commercial services, or commercial supporters with the exception of:

Laura Bachmann, MD, MPH, Chief Medical Officer, Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, GA and she wishes to disclose she has received research support from NIH, CDC, Becton-Dickenson, Atlas Genetics, Ltd. prior to taking federal position.

Clare Coleman, BA, President and CEO, National Family Planning & Reproductive Health Association (NFPRHA), Washington, DC and she wishes to disclose she is the President and CEO of National Family Planning & Reproductive Health Association (NFPRHA).

Matthew Golden, MD, MPH, Director and Professor, Public Health Seattle-King County HIV/STD Program, University of Washington Harborview Medical Center, Seattle, WA, he wishes to disclose he have received research support from Hologic.

Yonatan Grad, MD, PhD, Assistant Professor of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, MA, he wishes to disclose he is a Consultant and he have received consulting fees from GSK and Merck.

Lisa Manhart, PhD, Professor, Epidemiology & Global Health (adjunct), Center for AIDS and STD, University of Washington, Seattle, WA, she wishes to disclose she has received donations of reagents and test kits from Hologic, Inc. 

Blackford Middleton, MD, MPH, MSc, FACP, FACMI, FHIMSS, Chief Informatics and Innovation Officer, Apervita, Inc., Chicago, IL, he wishes to disclose he received research grants: Gordon and Betty Moore Foundation, AHRQ, Salary from Apervita, Inc.

Gregorio Millett, MPH, Vice President & Director, Public Policy amfAR, The Foundation for AIDS Research, Washington, DC, wishes to disclose he is Vice President & Director of the Public Policy amfAR, The Foundation for AIDS Research.

Susan Philip, MD, MPH, Deputy Health Officer, Director, Disease Prevention and Control Branch, Population Health Division, San Francisco Department of Public Health, San Francisco, CA, she wishes to disclose she is a textbook author with McGraw Hill Education and Research support to her institution: Roche Diagnostics.

Barbara Van Der Pol, PhD, MPH, Associate Professor of Medicine / STD Diagnostics Lab Director, University of Alabama at Birmingham School of Medicine, Birmingham, AL, she wishes to disclose she received consulting fees from Roche Molecular and SpeeDx in the past year.

Karen Wendel, MD, Director HIV/ STD Prevention and Control, Denver Public Health, Denver, CO, she wishes to disclose she has stock ownership in Pfizer.

David Whiley, PhD, Faculty of Medicine, The University of Queensland, Royal Brisbane Hospital, Brisbane, Queensland, Australia, he wishes to disclose he received research funding from SpeeDx Pty Ltd.

Planning committee discussed conflict of interest with Laura Bachmann, Clare Coleman, Matthew Golden, Yonatan Grad, Lisa Manhart, Blackford Middleton, Susan Philip, Barbara Van Der Pol, Karen Wendel, and David Whiley.

Content will not include any discussion of the Unlabeled Use of a Product or Product under Investigational Use with the exception of:

Laura Bachmann’s discussion on PL3.  Plenary 2: Defining STD Program Success in 2018: She will be discussing STI control in the 21st century: Can the past inform the future? She will discuss nucleic acid amplification tests for the diagnosis of the extra-genital gonococcal and chlamydia infection.

Stephanie Cohen’s discussion on D. Debate 1:  It is time to Implement Doxycycline Prophylaxis for Syphilis. She will be debating a non-FDA approved indication for doxycycline (i.e. for STD prophylaxis).

Edward Hook, III’s discussion on A2. Mini-Plenary 2: Innovations in the Pipeline: STD Vaccines and Novel Antibiotics. He will briefly summarize new drugs being developed for gonorrhea therapy.

Lisa Manhart’s discussion on H2. 4E – Symposium:  Emerging/Re-emerging and Neglected STI. She will be discussing data generated using analyte specific reagents, and resistance testing performed using research tests.

Barbara Van Der Pol’ discussion on B2. 1E – Symposium: Changing Paradigms for STI Diagnostics.  She will be discussing what’s on the way and where will it take us? She will discuss validated off-label use of diagnostic assa\ys (e.g. extra-genital testing for which no manufacturer has a claim).

David Whiley’s discussion on F1. Mini-Plenary 3: Drivers of Antimicrobial Resistance: The Community, the Individual and the Pathogen. He will be discussing molecular tools to examine antibiotic resistant N. gonorrhoeae. He will discuss a range of molecular methods that show promise for use in future gonorrhea investigations, bus most of which are not yet approved for diagnostic use.

The Centers for Disease Control and Prevention and the American Sexually Transmitted Diseases Association, the American Sexual Health Association, the National Coalition of STD Directors, the Public Health Agency of Canada, and the Pan American Health Organization, are jointly providing the CNE for this activity.

CDC did not accept commercial support for this continuing education activity.

INSTRUCTIONS FOR OBTAINING (CE)

In order to receive continuing education (CE) for WD2934-2018 STD Prevention Conference, please visit TCEO and follow these 9 Simple Steps by November 1, 2020 after reviewing the conference recordings.

Complete the Activity:

  1. View conference recordings for CE here. Not all sessions are available for CE (see agenda).
  2. Complete the Evaluation at www.cdc.gov/GetCE.

IMPORTANT: You may receive CE for only one presentation per time period. Furthermore, once you complete the Entire Conference Evaluation, you are unable to add additional sessions for CE.

The course access code is 2018 STD Conf.

FEES: There are no fees for CE activities.

 

 

TOP